Probiotic Prawn Oral Immunotherapy (ProPIT) for Treatment of Prawn Allergy

益生菌虾口服免疫疗法 (ProPIT) 用于治疗虾过敏

• 批准号: nhmrc : 1144965
• 负责人: Prof Andreas Lopata
• 金额: $ 126.12万
• 依托单位: Murdoch Childrens Research Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/probiotic-prawn-oral-prawn-allergy/1320319
• 关键词: Probiotic; Prawn; Oral; Immunotherapy; ProPIT

A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.

需要一种“治愈性”食物过敏治疗来预防死亡并改善护理。我们最近表明，益生菌花生口服免疫疗法 (PPOIT) 对于治疗花生过敏非常有效，82% 的接受 PPOIT 治疗的儿童获得了耐受性，而安慰剂组只有 4% 的儿童获得了耐受性。我们现在将测试益生菌-食品 OIT 组合治疗虾过敏的方法，如果成功，我们将确定第一种治疗虾过敏的方法和治疗其他食物过敏的平台。